topic

430 A phase II study of nivolumab + BMS-986016 (relatlimab) in patients with metastatic uveal melanoma(UM) (CA224–094)
Jose Lutzky, Jose Lutzky, Lynn Feun, William Harbour

Journal for ImmunoTherapy of Cancer Nov 2020, 8 (Suppl 3) A261-A262; DOI: 10.1136/jitc-2020-SITC2020.0430
429 Long-term analysis of MASTERKEY-265 phase 1b trial of talimogene laherparepvec (T-VEC) plus pembrolizumab in patients with unresectable stage IIIB-IVM1c melanoma
Georgina Long, Reinhard Dummer, Douglas Johnson, Olivier Michielin, Salvador Martin-Algarra, Sheryl Treichel, Edward Chan, Scott Diede, Antoni Ribas

Journal for ImmunoTherapy of Cancer Nov 2020, 8 (Suppl 3) A261; DOI: 10.1136/jitc-2020-SITC2020.0429
431 Prospective, randomized trial of the tumor lysate, particle only vaccine compared to the tumor lysate, particle-loaded, dendritic cell vaccine to prevent recurrence for resected stage III/IV melanoma
Patrick McCarthy, Lexy Adams, Robert Chick, Guy Clifton, Timothy Vreeland, Anne O’Shea, Phillip Kemp Bohan, Annelies Hickeron, Jessica Campf, John Myers, Tommy Brown, Diane Hale, Mark Faries, John Hyngstrom, Adam Berger, James Jakub, Jeffrey Sussman, Montaser Shaheen, Thomas Wagner, George Peoples

Journal for ImmunoTherapy of Cancer Nov 2020, 8 (Suppl 3) A262-A263; DOI: 10.1136/jitc-2020-SITC2020.0431
433 Talimogene laherparepvec (T-VEC) in combination with ipilimumab (IPI) versus IPI alone for advanced melanoma: 4-year interim analysis of a randomized, open-label, phase 2 trial
Igor Puzanov, Jason Chesney, Frances Collichio, Parminder Singh, Mohammed Milhem, John Glaspy, Omid Hamid, Merrick Ross, Philip Friedlander, Claus Garbe, Theodore Logan, Axel Hauschild, Celeste Lebbe, Min Yi, Wendy Snyder, Janice Mehnert

Journal for ImmunoTherapy of Cancer Nov 2020, 8 (Suppl 3) A263-A264; DOI: 10.1136/jitc-2020-SITC2020.0433
244 Novel respirable antisense oligonucleotide (RASON) approach to primary and metastatic human lung cancer: preliminary results in a model system employing spontaneous lung tumors in dogs
Jonathan Nyce

Journal for ImmunoTherapy of Cancer Nov 2020, 8 (Suppl 3) A263; DOI: 10.1136/jitc-2020-SITC2020.0244
434 Updated clinical data from the melanoma expansion cohort of an ongoing Ph1/1b Study of eganelisib (formerly IPI-549) in combination with nivolumab
Michael Postow, Ryan Sullivan, Ezra Cohen, Martin Gutierrez, David Hong, Conor Steuer, Jerry McCarter, Nora Zizlsperger, Jeff Kutok, Brenda O’Connell, Jennifer Roberts, Kara Page, Halle Zhang, Bartosz Chmielowski

Journal for ImmunoTherapy of Cancer Nov 2020, 8 (Suppl 3) A264-A265; DOI: 10.1136/jitc-2020-SITC2020.0434
435 A phase II trial of nivolumab plus axitinib in patients with anti-PD1 refractory advanced melanoma
Saba Shaikh, Yan Zang, Hong Wang, Xi Yang, Cindy Sander, Amy Rose, Diwakar Davar, Jason Luke, Hassane Zarour, John Kirkwood, Greg Delgoffe, Yana Najjar

Journal for ImmunoTherapy of Cancer Nov 2020, 8 (Suppl 3) A265; DOI: 10.1136/jitc-2020-SITC2020.0435
437 Adenovirus IL-12 and Docetaxel in Combination with Anti-PD1 as an Effective Treatment Strategy for TNBC
Wei Qian, Jianying Zhou, Roberto Rosato, Jenny Chang, Ann Anselme

Journal for ImmunoTherapy of Cancer Nov 2020, 8 (Suppl 3) A266; DOI: 10.1136/jitc-2020-SITC2020.0437
438 Synergy between SEA-CD40 and chemotherapeutics drives curative antitumor activity in preclinical models
Weiping Zeng, Haley Neff-LaFord, Sahar Ansari, Celine Jacquemont, Michael Schmitt, Shyra Gardai

Journal for ImmunoTherapy of Cancer Nov 2020, 8 (Suppl 3) A266-A267; DOI: 10.1136/jitc-2020-SITC2020.0438
442 ICT01, an anti-BTN3A mAb that activates Vg9Vd2 T cells, plus interleukin-2: a potent and promising combination for cancer immunotherapy
Aude de Gassart, Patrick Brune, LE Suong, Sophie Agaugué, Emmanuel Valentin, Jennifer Sims, Daniel Olive, Paul Frohna, Rene Hoet

Journal for ImmunoTherapy of Cancer Nov 2020, 8 (Suppl 3) A268-A269; DOI: 10.1136/jitc-2020-SITC2020.0442

Main menu

topic

Pages

Log in using your username and password

Main menu

Log in using your username and password

You are here

topic

Pages